Peroxisome proliferator-activated receptors in macrophage biology: friend or foe?
- 1 October 2001
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Lipidology
- Vol. 12 (5), 519-527
- https://doi.org/10.1097/00041433-200110000-00007
Abstract
Peroxisome proliferator-activated receptor (PPAR)-gamma is a nuclear hormone receptor, with a well-established role in adipogenesis and glucose metabolism. Over the past 3 years several laboratories have reported that this protein can influence macrophage responses to a variety of inflammatory stimuli. The effect of PPAR-gamma activation on macrophage lipid uptake, cholesterol efflux, and cytokine production have all recently been examined in several in-vitro culture systems. In addition, PPAR-gamma ligands have been shown to influence atherosclerotic lesion formation in murine models of that disease. This review attempts to summarize and critically evaluate that work and its implications for the use of PPAR-gamma activators in understanding and treating the pathogenetic processes that contribute to atherosclerotic plaque formation.Keywords
This publication has 44 references indexed in Scilit:
- Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator–activated receptor γJournal of Clinical Investigation, 2000
- Two Opposing Effects of Non-steroidal Anti-inflammatory Drugs on the Expression of the Inducible CyclooxygenaseJournal of Biological Chemistry, 2000
- Prostaglandins Up-Regulate Vascular Endothelial Growth Factor Production through Distinct Pathways in Differentiated U937 CellsBiochemical and Biophysical Research Communications, 2000
- Activation of PPARα or γ Reduces Secretion of Matrix Metalloproteinase 9 but Not Interleukin 8 from Human Monocytic THP-1 CellsBiochemical and Biophysical Research Communications, 2000
- Nuclear Receptor Coregulators: Cellular and Molecular BiologyEndocrine Reviews, 1999
- PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDLCell, 1998
- Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγCell, 1998
- Another Potential Use of Troglitazone in Noninsulin-Dependent Diabetes MellitusJournal of Clinical Endocrinology & Metabolism, 1998
- Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study GroupDiabetes, 1997
- Inhibition of oxidation of low density lipoprotein by troglitazoneAtherosclerosis, 1996